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ABSTRACT 
Raynaud’s phenomenon (RP) is a chronic episodic attack of digital ischemia provoked by exposure to cold or 
emotional stres. This phenomenon affects 3-5% of the population, with female ratio more than men and is 
categorized into a primary and secondary form. Primary form of RP is idiopathic, meanwhile the secondary form 
is associated with underlying diseases and other condition such as connective tissue disease, obstructive arterial 
disease, neurologic disorders, drugs and toxin, hyperviscosity disorders, infections, endocrine disturbance, 
neoplasms, and occupation or environmental exposure. Until today, to classified and build the diagnosis of RP is 
still a clinical challenge. Therefore, a careful history and a physical examination, together with laboratory tests 
and nailfold capillaroscopy are mandatory. A combination of conservative measures and medications can help in 
the management of RP. The approach to the RP patients requires therefore a coordinated care of specialists 
including dermatology.  
Keywords: Raynaud’s phenomenon, diagnosis, management 
 
Introduction 
Raynaud's phenomenon (RP) is an episodic digital ischemia that occurs due to cold 
stimulus or emotional stress. This phenomenon is characterized by a series of changes in the 
color of the fingers called triphasic color, which is white (pallor), blue (cyanosis), and red 
(rubor), accompanied by numbness and ended with episodes of pain.1 
Raynaud's phenomenon is divided into primary and secondary RP. Raynaud's 
phenomenon is more likely to be used to refer to secondary RP, whereas primary RP is often 
referred to as Raynaud's disease. The primary Raynaud phenomenon is idiopathic, whereas 
secondary RP arises because of an underlying disease or condition. In its journey, the 
transitions from primary RP to secondary RP can occur.2 
The prevalence of RP varies among different geographical areas, depending on climate, 
ethnicity, and diagnostic methods.3 The prevalence of this phenomenon in the general 
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population is around 3-5%,4 with primary RP more often occur than secondary RP, and more 
often occur in women than men.5 The highest prevalence of secondary RP is in patients with 
systemic sclerosis or scleroderma and mixed connective tissue disease (MCTD), reaching 90% 
or more. In addition, systemic rheumatic diseases such as systemic lupus erythematosus (SLE), 
primary Sjögren's syndrome, rheumatoid arthritis (RA), and polymyositis can also cause 
secondary RP.6 
The pathophysiology of vasospasm as a cause of RP is complex and not yet fully 
understood. Abnormalities in the central control mechanism of thermoregulation, vascular, 
neural, intravascular factors, and other factors such as hormones and genetics play a role in the 
occurrence of RP.7 
A careful history and physical examination are important in the evaluation of RP patients. 
The main thing in RP diagnosis is, knowing that RP is dividing into the primary or secondary 
form. A clear description of an ischemic attack will help identify signs and symptoms that 
indicate a secondary cause.8 In addition, severe RP complications such as ulcers and gangrene, 
generally occur in secondary RP. Gold standard examination for RP is nail fold capillaroscopy. 
The management of RP depends on the frequency, severity of attacks, and complications 
of ischemia. Primary Raynaud's phenomenon is generally easy to control with lifestyle 
changes, while secondary RP needs to be treated according to the underlying disease or 
condition, which makes comprehensive management is needed. Medication is given if RP 
attacks are prolonged or fail to be treated conservatively. Calcium channel blockers (CCB) are 
by far the most widely used and effective way to treat RP.9 
 
Classification 
Raynaud's phenomenon is divided into primary and secondary RP. The difference 
between the two types of RP is based on the presence or absence of underlying causes or 
diseases. Primary Raynaud's phenomenon or Raynaud's disease arises without underlying or 
idiopathic causes. While secondary RP or also called Raynaud's syndrome or phenomenon, 
arises due to various causes.1 Primary Raynaud's phenomenon generally first arises in 
adolescence in the range of 15-30 years, while secondary RP arises at age > 25 years.10,11 
About 1-3% of primary RP patients per year develop into secondary RP, especially in 
patients with systemic sclerosis. This is presumably because in addition to inaccuracies in the 
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initial classification as primary RP, it can also be caused by RP in the early phase of connective 
tissue disease that can manifest clinically similar to primary RP.2 
 
Etiology And Pathogenesis 
Raynaud was the first person who reveal the initial etiology of RP. He mentioned that 
RP is a local asphyxia of the extremities caused by disorders of the central nervous system 
(CNS), which then affected the innervation of blood vessels. Lewis and Pickering, however, 
estimate that RP is a local defect caused by digital arterial spasm and not a secondary result of 
CNS damage.12 Raynaud's phenomenon proved to be provoked not only by local cold exposure 
but also by stress, which implies that both local and central mechanisms are involved.7  
Risk factors for primary RP include genetic factors, smoking habits, and a history of 
migraine.3 While secondary RP can be caused by several diseases or conditions as can be seen 
in table 1. 
 
Table 1. Disease and Condition Causing Secondary RP 
DISEASE/CONDITION Type 
Connective Tissue disease Scleroderma 
SLE 
Dermatomyositis and polimiositis 




Arterial obstruction disease Atherosclerosis 
Thromboangiitis obliterans (TAO) 
Thromboembolism 
Thoracic outlet syndrome 











Agen kemoterapi (bleomycin, vinblastine) 
Work Jobs that require prolonged cold temperatures to the extremities 
Work that uses a vibrating device 
Hyperviscosity disorder Cryoglobulinemia 
Macroglobulins 
Cold agglutinin 




                                                                                                         










Connective tissue disease is the most common cause of secondary RP. A range of 80-
90% of scleroderma patients experience persistent RP and/or vasospasm. Raynaud's 
phenomenon can be the only clinical manifestation that has existed for years.9 
According to Herrick et al, there are at least four things that underlie the pathogenesis of 
RP, including (1) vascular, (2) neural, (3) intravascular, and (4) other factors.7 
 
1. Vascular 
Vascular abnormalities in RP consist of (1) vasodilation disorders, (2) increase in 
vasoconstriction, and (3) abnormalities or changes in microvascular structures and digital 
arteries. The primary Raynaud phenomenon is caused by impaired vascular and/or nerve 
function, and does not risk irreversible tissue damage, while secondary RP is caused by changes 
in vascular structure and results in tissue damage such as digital ulceration, scarring, or 
gangrene.7 
Changes in vascular function in the RP are primarily on the endothelium which plays a 
role in regulating vascular tone by producing a number of vasodilator mediators such as nitric 
oxide (NO), and vasoconstrictor mediators such as endothelin-1, and angiotensin.6,7 Activation 
and/or endothelial damage will disturb the balance between vasodilation and vasoconstriction 
which results in less vasodilator production or effectiveness and/or excessive vasoconstrictor 
production.6 Disorders of endothelial cells can cause vasoconstriction even without damage to 
vascular structures.7 
2. Neural 
Neural factors in the pathogenesis of RP play a role in conditions caused by direct 
disorders of the sympathetic nervous system, vasodilation disorders, excessive 
vasoconstriction, and central mechanisms.7,9 
One of the neurotransmitters vasodilatation that plays a role is calcitonin-gene related 
peptide, with decreased immunoreactivity in the finger skin of RP patients. In addition, there 
is a disruption in the function of alpha-2 adrenergic receptors that play a role in regulating 
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vascular tone. Sensitivity to cold is thought to be caused by alpha-2C adrenergic receptors, 
which move from the golgi compartment to the cell surface in response to cold. The relocation 
of alpha-2C adrenergic receptors is induced by Rho kinase, which is stimulated by reactive 
oxygen species (ROS) produced in smooth muscle cells in response to cold. Arteriol 
vasoconstriction is also associated with increased activity of tyrosine kinase protein and 
tyrosine phosphorylation in both primary and secondary RP. In addition, nonadrenergic 
mechanisms, such as the neuropeptide Y pathway, can also contribute to skin vasoconstriction.7 
Although the central mechanism alone cannot fully explain the process in RP, many RP 
patients experienced vasospasm induced by stress. This shows the influence of the CNS. 
According to research conducted by Freedman et al, the range of one third of primary RP 
attacks is caused by emotional stress, whereas secondary RP is less affected by stress. Several 
studies investigating the effects of emotional stress on vascular tone and digital perfusion in 
RP patients have produced mixed conclusions, and none can explain the role of the sympathetic 
nervous system in the pathogenesis of this disorder. However, studies of cardiovascular 
responses that are triggered by stressors in RP patients show impaired ability to deal with 
repetitive stress stimuli, which shows changes in CNS control of the cardiovascular system.12 
3. Intravascular 
Several factors in circulation have been shown to be involved in the pathogenesis and 
exacerbation of RP, particularly when associated with secondary RP, especially systemic 
sclerosis. The roles of platelet activation, fibrinolysis damage, and oxidative stress have been 
reported. Although the role of these factors is not fully understood, these intravascular factors 
can exacerbate digital vasospasm by reducing blood flow in the microvasculature.12 
4. Other Factor 
Other factors that play a role in the pathogenesis of RP include the estrogen hormone, 
and genetic factors. The role of estrogen in vascular disorders has long been suspected, because 
women dominate blood vessel disorders such as primary pulmonary hypertension and 
migraine. In addition, a higher prevalence of RP in women, and an increase in RP in the phase 
between menarche and menopause proves that differences in sex and hormonal factors are 
important.7,8 The effects of estrogen on vascular tone are not fully understood, so 
recommendations for estrogen use or restriction in RP patients seem still too early.12 
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A study using whole genome linkage analysis in family members with RP identified 3 
potential gene candidates, namely the beta acetylcholine receptor muscle subunit, serotonin 1B 
and 1E receptors. Other studies report a higher prevalence of migraines in primary RP patients, 
with migraine symptoms more evident in patients who have a family history of RP. These 
findings indicate that primary RP is part of a broader vascular tone disorder with genetic 
predisposition.12 About 30-50% of primary RP patients has first-degree relatives who also 
experience primary RP.10 In addition, genetic factors are also involved in the pathogenesis of 
secondary RP especially systemic sclerosis.12 
 
Clinical Manifestation 
Patients with RP commonly complain about episodic attacks due to cold exposure and 
emotional stimulation in the form of triphasic color changes that are clearly demarcated, start 
with white (pallor) due to ischemia, then blue (cyanosis) due to deoxygenation, and finally red 
(hyperemia) due to reperfusion. Complete changes in these three colors are rarely seen, most 
of which only show pale fingers accompanied by numbness (figure 1).2 Most experts believe 
that changes in white and blue biphasic color are sufficient for clinical features of RP, with the 
pallor phase being the most important of the 2 other color change phase.1,10  
 
 
Figure 1. Clinical manifestations of RP. A. Pallor phase. B. Cyanosis phase 10 
 
The most commonly affected body parts by RP are the fingers and toes. Raynaud's 
phenomenon however can also occur on the tongue (figure 2), nose, ears, or nipples.3 During 
an attack, one or more fingers become numb. When warmed, the finger becomes bright red, 
and can be accompanied by throbbing pain. Attacks can last for several minutes, up to several 
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hours.9,13 The frequency of attacks on primary RP is <5 times per day, while secondary RP 
attacks can occur 5 to 10 times per day.11 
 
Figure 2. Clinical Manifestation of RP on Tongue. A. Normal tongue, B. Tongue during RP ischemic attack.14 
 
In primary RP, vasospasm attacks are generally symmetrical, but often only affect a 
portion of the finger, and without thumb involvement. Attacks on primary RP also quickly 
improve with warmth, and no ischemic injury is seen.10,15 
In secondary RP, asymmetrical vasospasm attacks occur with thumb involvement. The 
attacks are intense, frequent, accompanied by pain in the ischemic phase, edema, and are at 
risk of ischemic injuries such as ulcers on the finger pads or around the nail bed, or gangrene. 
The ulcer will then heal slowly, leaving a characteristic scar tissue in the form of a point called 
digital pitting or pitting scar (figure 3).2 
 
 
Figure 3. Pitting scar on secondary RP.2 
 
In addition, nail dystrophy, skin atrophy, calcinosis, telangiectasia, sclerodactile, and hair 
loss on the dorsal surface of the fingers in secondary RP patients caused by persistent vascular 
abnormalities can also occur (figures 4).2,9,15 
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In secondary RP caused by TAO, the pulse in both arms can be asymmetrical, so the 
overall pulse and blood pressure of both arms must be checked.9,16 In addition, it is necessary 
to look for muscle weakness, joint pain, dry eyes and mouth or sicca symptoms, as well as 
complaints of heartburn that indicate esophageal dysmotility to see possible secondary causes 
of connective tissue disease, especially scleroderma.2,8 
 
Additional Examination 
Examination for RP consist of Allen tests, laboratory tests, and non-invasive tests.9 
1. Allen Test 
The Allen test is useful for assessing the function of arteries and capillaries of the hand. 
In this test, the radial and ulnar arteries are simultaneously compressed by the examiner's 
thumb, while the patient clenches his fists for 30 seconds. After that, the patient asked to open 
his hands, and the patient's hands can be seen pale. Pressure is released from the ulnar artery 
but the radial artery is maintained. If the hand's color returns within 5-15 seconds, arterial 
function is considered normal. Abnormal filling indicates structural abnormalities of the 
microcirculation and increases suspicion of secondary RP.9,17 
2. Laboratory Test 
In RP patients, laboratory tests that need to be done are complete blood tests, erythrocyte 
sedimentation rates, and ANA tests.2,9 ANA tests help identify RP patients who are at risk for 
connective tissue disease. This test should be a routine examination in secondary RP patients 
because >90% of secondary RP is due to connective tissue disease. Additional laboratory tests 
can be carried out according to the findings on history taking and physical examination.2 
3. Non-invasive test 
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Some non-invasive tests that can be performed on RP are capillaroscopy, infrared 
termography (IRT), Doppler ultrasound, finger systolic pressure measurement, and 
plethysmography.2 
Capillaroscopy is the gold standard examination for RP. This examination aims to see 
the morphology of the capillaries in the nail fold dermis papillae. The image of a normal distal 
capillary row is hairpin-shaped loops that are parallel to the finger axis. Mild capillary 
abnormalities in the form of twisted capillaries can be seen in primary RP patients.2  
In secondary RP particularly due to scleroderma, there are typical capillaryoscopic 
features such as capillary dilation, decreased capillary count, bleeding, and neoangiogenesis.2 
IRT cameras measure infrared emissions to estimate the surface temperature of an object. 
This tool is used clinically to assess disease progression and therapeutic response. Changes in 
skin temperature due to perfusion and blood flow can be detected by IRT, so that indirect 
measurements can be made of skin microvascular function.2 
Laser Doppler technique, arterial Doppler ultrasound, finger systolic pressure, and 
plethysmography are RP diagnosis techniques that are used in research and are not used 
routinely for clinical assessment.2 
 
Diagnosis 
The diagnosis of RP is built on the basis of history, clinical manifestations, and additional 
examination, all of which aim to identify whether the RP is primary or secondary.9 
There are diagnostic criteria for primary RP, including (1) vasospastic attacks 
precipitated with cold exposure or emotional stimulation, (2) bilateral limb involvement, (3) 
examination of blood vessels, peripheral pulses, and capillary microscopy of normal nail fold, 
(4) absence of gangrene or, if present, limited to fingertip skin, (5) no underlying disease, drug, 
or occupational exposure that causes a vasospasm attack, (6) a negative ANA test, (7) normal 
erythrocyte sedimentation rate, and (8) history symptoms for at least two years.9 A summary 
of the evaluation of RP can be seen in Figure 7. 
 
Differential Diagnosis 
Some skin diseases related to temperature sensitivity can mimic RP, such as frostbite, 
chilblains, lupus chilblains, acrosianosis, livedo reticularis, and erythromelalgia. This disease 
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is distinguished based on the cause, skin character and tissue changes, and the course of the 
disease.2 
Frostbite is an ischemic condition due to extreme and prolonged cold exposure. Frostbite 
and RP are caused by temperature sensitivity, which is mainly concerning the extremities. 
Patients with RP are at risk of suffering from frostbite, and conversely frostbite can increase 
the risk of RP. Raynaud's phenomenon improves with heating, and generally in mild to 
moderate cases is limited to white, blue or red. Severe finger ischemia in secondary RP can 
resemble frostbite images, with digital violaceous, multiple, and necrotic ulcers.2 
Chilblains are cold induced vasculopathies that are more commonly seen in humid 
climates and are not associated with systemic diseases. This condition mainly affects the hands 
and feet with bilateral symmetrical distribution and is more common in young women. 
Inflammatory lesions typically in the form of purplish red macules can be seen at the distal end 
of the affected area, and usually arise within a few hours after cold exposure. Burning, pain, 
and/or pruritus, swelling of small joints in the area involved, and ulceration, often accompany 
lesions. Acral lesions on chilblains tend to be more discrete, and in the acute phase there are 
no pallors. In addition, although warmed, chilblains lesions are more persistent than RP 
lesions.2 
Lupus chilblains are a chronic and rare form of cutaneous LE. Lesions are characterized 
by erythematous to purple plaques located in the distal extremities, and sometimes in the nose 
or ears.4 These lesions are induced by cold exposure or a decrease in temperature, may 
accompanied by mild pain, pruritus, or hyperhidrosis. Changes in pigment and scar tissue 
atrophy can be seen. Lupus chilblains and RP can occur together or stand-alone.2 
Acrosianosis is a change in finger color or the face becomes cyanotic, persistent, 
symmetrical, painless, induced by exposure to cold temperatures. This condition is often 
accompanied by local hyperhidrosis of the hands and feet. Acrosianosis can arise as a primary 
or idiopathic condition, or as a secondary manifestation of other diseases. The difference 
between acrocyanosis from RP is that discoloration in acrocyanosis is persistent, whereas RP 
is reversible. There is no pallor phase in acrocyanosis, and is not accompanied by pain.2 
Livedo reticularis is a vascular pattern like a violet-colored web on the skin that is become 
pale with pressure. This condition is mainly suffered by young women and is often found in 
the lower extremities. Livedo reticularis can be a normal physiological condition that 
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disappears when warmed up, or it can also be a marker of hypercoagulable abnormalities. 
Livedo reticularis and RP are both associated with cyanotic discoloration due to cold exposure, 
and disappear when warmed. The difference is at its predilection, livedo reticularis especially 
attack the skin in the proximal extremities such as the thighs and knees, while the RP is more 
common in the acral region.2 
Erythromelalgia is a condition in the form of an attack of burning or stabbing pain in the 
skin of the extremities induced by warm temperatures in the range of 32-36°C. Both RP and 
erythromelalgia are conditions due to sensitivity to temperature, often accompanied by pain, 
especially regarding the hands and feet although it is more common in the lower extremities, 
and the present of erythematous phase. Erythromelalgia and RP, but differ in several respects. 
First, the ischemic phase in RP is not found in erythromelalgia. Erythromelalgia also improves 
with elevation of the extremities, and by cooling.4 
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 Figure 7. Chart of patient evaluation of Raynaud's phenomenon1 
RP Patient 
Asymmetric attacks / one finger, 
no palpation, asymmetrical 
blood pressure or tissue 
necrosis 
 
Symmetrical attacks without 
complications 
Exclude possible structural 
abnormalities of medium or 
large blood vessels (eg thoracic 
outlet syndrome) with vascular 
examination (Doppler 
ultrasound, angiography)  
Exclude: 
- Environmental exposure 
(e.g. vibration, cold sores) 
- Exposure to chemicals (e.g. 
vinyl chloride) 
- Drugs (e.g. bleomycin) 




- Pitting scar 
- Digital ulcer 
Nail folding capillaryoscopy examination: 
- Enlarged capillary loop, capillary looks broken 
Evaluate symptoms of other connective tissue diseases 
ANA Test 
RP primer 




+ anti-topoisomerase I Ab, 
+ anti-centromere Ab, or pattern 
    Nuclear ANA 
and / or 
There is a clinical picture of 
systemic sclerosis 
+ anti-RNP, SS-A / SS-B, Sm, or 
    dsDNA antibodies 
and / or 
There is a clinical picture of other 




the signs and 
symptoms of 
connective tissue 
disease or other 
systemic disease Secondary RP to systemic 
sclerosis 
Secondary RP to other 
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Management 
The management of RP depends on the frequency, attacks severity, and ischemic 
complications. In secondary RP, treatment according to the underlying disease, discontinuation 
of the drug causing vasospasm, or work modification is needed. Drugs are generally given to 
patients with prolonged attacks or who fail to be treated with conservative measures. If there 
is a state of severe ischemia or a finger ulcer that is resistant, and therapy with a vasodilator is 
not able to improve blood flow, then surgery such as digital sympathectomy is necessary.9 
1. General Management 
General or conservative management for RP consists of educating patients to change 
lifestyles, specifically avoiding cold exposure, stopping smoking, stress modification, and 
education so that patients do not feel anxious.10 
Avoiding cold is the most effective therapy, and is then key in successful attacks 
managing in all patients.2 Local and systemic warmth is effective for increasing skin blood 
flow. The use of gloves, soaking and rubbing hands in warm water, or using a hair dryer can 
help prevent attacks or speed recovery. Generally ischemic attacks still last 15-20 minutes after 
warming. Systemic warm up can be done by keeping the whole body warm with loose padded 
clothing, gloves, and head coverings; keep the room temperature several degrees higher than 
normal; avoid rapidly changing temperatures, such as rushing to an air-conditioned area; 
limiting the time outdoors in winter; and avoid cold and windy conditions.9,10 
Smoking habits must be stopped, and other people's cigarette smoke should be avoided, 
because nicotine induces skin vasoconstriction.9 
Stress modification, for example with counseling and relaxation training, and social 
support are important aspects of RP. This is because stress modification can minimize 
vasoconstriction due to hyperactivity of the sympathetic nervous system.9,10 
Pain control is an important part of therapy, because pain for example in ulcers can 
cause additional vasospasm and aggravate ischemia.9 
2. Drugs 
Some classes of drugs that can be used for RP are, (1) calcium channel blockers (CCB), 
(2) phosphodiesterase type 5 inhibitors (PDE-5), (3) topical nitrates, (4) angiotensin II-receptor 
blockers (ARBs), (5) selective serotonin reuptake inhibitors (SSRIs), (6) anti-platelets, (7) 
prostanoids, (8) botulinum toxin type A (BTX-A), and (9) endothelin inhibitors 1. In general, 
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therapeutic responses better in primary RP patients. This is presumably because in secondary 
RP there has been permanent structural damage.9 Guidelines for the use of RP drugs can be 
seen in figure 14. 
1) Calcium Channel Blockers 
Calcium channel blockers are an effective first choice drug for treating RP. It is 
based on, calcium channels allow calcium activators to enter smooth muscle cells 
and initiate vasoconstriction.2 
Calcium channel blockers of dihydropyridine, especially nifedipine, are the 
most commonly used because they are less cardioselective. Nifedipine at a dose of 
10-20 mg 3-4x/day can reduce the severity and frequency of attacks. Long-acting 
nifedipine preparations that are at doses up to 90 mg/day are better tolerated but 
may be less effective in the acute phase.2 Diltiazem is a benzothiazepine CCB that 
can be used if nifedipine is ineffective or not well tolerated, with a dose of 60 mg 
3x/day or 4x/day. Side effects of CCB include fluid retention, light dizziness, and 
heartburn.9 
2) Phosphodiesterase type 5 inhibitors (PDE-5) 
Phosphodiesterase is a group of enzymes that help regulate intracellular 
nucleotide cycle degradation. Phosphodiesterase type 5 degrades the guanosine 
monophosphate (GMP) cycle, which is the main mechanism for NO to cause 
vasodilation. PDE-5 inhibitors strengthen the vasodilator effect of NO, so this drug 
can be useful in the treatment of RP.7 This drug can be used single or in combination 
with CCB.10 
3) Topical nitrates 
Nowadays, the most widely used approach to handling resistant RP cases is 
drugs that can mimic or strengthen vasodilators and protective activity by 
endothelium-derived nitrite oxide. Topical nitrate, also called transdermal nitrate, 
which is available in patches, creams, gels and ointments, has been reported to 
reduce the frequency and severity of vasospastic attacks in primary and secondary 
RP patients without serious side effects. Nitric oxide causes dilation by stimulating 
guanylate cyclase and increasing the GMP cycle, which is then degraded by the 
enzyme PDE.18 This drug, can be used singly or in combination with CCB.10 
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4) Angiotensin II-Receptor Blockers (ARBs) 
Angiotensin II-receptor blockers are drugs used for hypertension and other 
conditions that respond to angiotensin II blockade. The group of ARBs drugs most 
often used for the treatment of RP is losartan at a dose of 50 mg / day.2 
5) Selective Serotonin Reuptake Inhibitors (SSRIs) 
There are several studies evaluating the use of SSRIs as RP’s therapy. Selective 
serotonin reuptake inhibitors inhibit the reuptake of large amounts of serotonin in 
platelets. Digital vasodilation is likely to be partly mediated through the CNS 
blockade of serotonin reuptake by SSRI.12 
Selective serotonin reuptake inhibitors are antidepressants and antianxiety, so 
they can be useful for RP patients with anxiety disorders. The most commonly used 
SSRI class is fluoxetine at a dose of 20 mg / day.2 
6) Anti-platelets 
Anti-platelet drugs on RP specifically used for the treatment of ulcers on the 
fingers of systemic scleroderma patients. Anti-platelets are mainly used in patients 
who have a coagulation defect as an underlying disease.12 
Anti-platelet therapy with a dose between 75-81 mg/day can be considered 
during an acute ischemic attack. This therapy is best used on secondary RP caused 
by emboli or vascular blockage process that occurs in thrombosis.12 
7) Prostanoids 
Prostanoids, also called prostacyclin or epoprostenol, are powerful vasodilators 
that act on pulmonary and systemic vascularization. This drug has many biological 
effects, including inhibiting smooth muscle proliferation, endothelial cell 
protection, and inhibiting platelet aggregation. Intravenous preparations are the 
form most often used for the treatment of severe secondary RP especially due to 
systemic sclerosis.2 
8) Botulinum Toxin Type A (BTX-A) 
Local injection of BTX-A on the RP can reduce pain, improve blood flow, and 
increase finger temperature, thereby contributing to ulcer healing. For each hand, 
50 BTX-A units are injected into the palm around the neurovascular bundle as high 
as the metacarpophalangeal joint. Four BTX-A units are injected around the para-
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ulnar artery and the para-radial artery, and 2 units each at the beginning of the 
common palmar digital artery, around the initial part of the digital palmar proper 
artery and the para-proper palmar digital artery. The injection is done with a 30-
gauge needle connected to a 1 cc syringe.19 
9) Endothelin inhibitors 1 
Bosentan is an endothelin-1 inhibitor that has been shown to be effective in the 
treatment of pulmonary hypertension due to idiopathic causes and systemic 
sclerosis. The similarity in abnormalities in vascular function and structure in 
pulmonary hypertension due to systemic sclerosis and RP stimulates clinical 
research to study the effectiveness of bosentan in RP. Bosentan can reduce the 
number of new ulcers, but does not improve healing of existing ulcers, reduce the 
frequency, or severity of RP attacks.12 
 
 
Figure 14. RP management chart.10 
First line for mild-moderate RP: 
• Begin with sustained release dihydropyridine-class calcium-channel 
blockers (CCB) such as nifedipine, amlodipine, or felodipin. 
• If there are side effects to CCB, other options are phosphodiesterase 
type 5 inhibitors (PDE-5), topical nitrates, angiotensin-receptor 
blockers (losartan), or selective serotonin reuptake inhibitors (SSRIs) 
Second line for severe RP or ischemic digital lesions: 
Combination therapy, namely: 
• CCB + PDE-5 inhibitors (sildenafil / tadalafil) or CCB + topical nitrate 
• Add antiplatelet medication (aspirin 81 mg)  
Third line for severe recurrent RP or repetitive digital ischemic lesions: 
• Add prostanoids (epoprostenol or iloprost) or injection of botulinum 
toxin, or both 
• Start therapy with an endothelin-1 inhibitor (bosentan) for scleroderma 
with recurrent digital ulcers 
Fourth line for severe digital ischemia with the threat of gangrene or 
amputation:  
• Drug therapy + digital sympathectomy  
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